案例研究1：探索治疗2型糖尿病的药物制剂。 - Suppr

Suppr

超能文献

Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.

作者信息

Martin Catherine L

机构信息

Michigan Diabetes Research and Training Center, University of Michigan Health System, Ann Arbor, Michigan, USA.

出版信息

Diabetes Educ. 2007 Jan-Feb;33 Suppl 1:6S-13S. doi: 10.1177/0145721706298434.

DOI:10.1177/0145721706298434

PMID:17272803

Abstract

摘要

相似文献

Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.

Diabetes Educ. 2007 Jan-Feb;33 Suppl 1:6S-13S. doi: 10.1177/0145721706298434.

Safety of very tight glucose control in type 2 diabetes in question.

Diabetes Obes Metab. 2008 May;10(5):438. doi: 10.1111/j.1463-1326.2008.00906.x.

Individualizing glycemic targets in type 2 diabetes mellitus.

Ann Intern Med. 2011 Sep 6;155(5):340-1. doi: 10.7326/0003-4819-155-5-201109060-00025.

Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?

JAMA. 2017 Mar 14;317(10):1017-1018. doi: 10.1001/jama.2017.0029.

Importance of glycemic control.

J Fam Pract. 2011 Sep;60(9 Suppl):S4-6.

Diabetes specialists keep ACCORD data in perspective.

Am J Health Syst Pharm. 2008 Mar 15;65(6):488, 490. doi: 10.2146/news080021.

[Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].

MMW Fortschr Med. 2008 Apr 24;150(17):42-4. doi: 10.1007/BF03365441.

A summary of the ADVANCE Trial.

Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S357-61. doi: 10.2337/dc09-S339.

Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.

Nutr Metab Cardiovasc Dis. 2017 Apr;27(4):375-377. doi: 10.1016/j.numecd.2017.01.003. Epub 2017 Jan 16.

[Hypoglycemia and cardiovascular risk].

G Ital Cardiol (Rome). 2014 Dec;15(12 Suppl 2):4S-12S. doi: 10.1714/1762.19110.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.

Diabetes Educ. 2007 Jan-Feb;33 Suppl 1:6S-13S. doi: 10.1177/0145721706298434.

Safety of very tight glucose control in type 2 diabetes in question.

Diabetes Obes Metab. 2008 May;10(5):438. doi: 10.1111/j.1463-1326.2008.00906.x.

Individualizing glycemic targets in type 2 diabetes mellitus.

Ann Intern Med. 2011 Sep 6;155(5):340-1. doi: 10.7326/0003-4819-155-5-201109060-00025.

Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?

JAMA. 2017 Mar 14;317(10):1017-1018. doi: 10.1001/jama.2017.0029.

Importance of glycemic control.

J Fam Pract. 2011 Sep;60(9 Suppl):S4-6.

Diabetes specialists keep ACCORD data in perspective.

Am J Health Syst Pharm. 2008 Mar 15;65(6):488, 490. doi: 10.2146/news080021.

[Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].

MMW Fortschr Med. 2008 Apr 24;150(17):42-4. doi: 10.1007/BF03365441.

A summary of the ADVANCE Trial.

Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S357-61. doi: 10.2337/dc09-S339.

Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.

Nutr Metab Cardiovasc Dis. 2017 Apr;27(4):375-377. doi: 10.1016/j.numecd.2017.01.003. Epub 2017 Jan 16.

[Hypoglycemia and cardiovascular risk].

G Ital Cardiol (Rome). 2014 Dec;15(12 Suppl 2):4S-12S. doi: 10.1714/1762.19110.